Macitentan denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Macitentan as Experimental — And Why You Can Appeal

Macitentan is an FDA-approved medication indicated for the treatment of pulmonary arterial hypertension (PAH). A denial characterizing macitentan as "experimental" or "investigational" is a denial that conflicts with its established regulatory status and its recognized position in PAH treatment guidelines from the applicable professional societies. These denials are among the most commonly overturned on appeal because they rest on a factual premise — that the therapy is unproven — that is contradicted by the public record.

## Why This Denial Is Appealable

An insurer's experimental/investigational determination must be based on whether the treatment lacks sufficient clinical evidence for the proposed use. Macitentan's FDA-approved indication for PAH, combined with its inclusion in the guidelines of the relevant cardiology and pulmonary hypertension professional societies, provides a strong factual foundation to challenge this characterization. Your appeal should anchor on the regulatory approval status (confirmed via the FDA label) and on your prescriber's explanation of why this is a medically recognized, non-experimental treatment for your diagnosis.

## Federal Appeal Framework

• Internal appeal: File within the timeframe stated in the denial letter (typically 180 days for ERISA plans). Standard appeals: 60 days. Expedited: 72 hours if clinically urgent.
• External review (ACA §2719): Experimental/investigational denials are specifically eligible for independent external review. An accredited IRO will evaluate whether the treatment meets the evidentiary standard for established therapy. The external review window is generally within four months of the final internal denial.
• Expedited external review: Available for urgent situations; can run simultaneously with expedited internal appeal.
• ERISA §503: Employer-sponsored plans must allow a full-and-fair review of all submitted evidence.

## Documentation to Gather

• FDA-approved prescribing information: the full label for macitentan confirming its approved indication for PAH
• Diagnosis confirmation: cardiology or pulmonary hypertension specialist records confirming the PAH diagnosis and classification
• Prescriber medical-necessity letter: from your PAH specialist, explaining that macitentan is not experimental — it is an FDA-approved, guideline-supported therapy being used for its approved indication
• Relevant guideline organization references: a general reference to the applicable PAH or cardiovascular guideline body that includes macitentan in its treatment algorithm (without citing specific statistics)
• Aetna's coverage policy: identify the exact language characterizing macitentan as experimental and address each element of that characterization

## Criteria-Mapping Structure

Organize your appeal to directly address Aetna's stated basis for the experimental classification. For each criterion Aetna applied, provide a point-by-point rebuttal supported by the FDA label, your clinical records, and your prescriber's letter. Make clear that the therapy is being used for its FDA-approved indication. Attach all referenced records as labeled exhibits.